{
    "nctId": "NCT00728156",
    "officialTitle": "Assessment of Platelet-dependent Thrombosis by an ex Vivo Arterial Injury Model: a Placebo Controlled Trial of Clopidogrel as Antiplatelet Therapy in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease",
    "inclusionCriteria": "* Patients with T2DM and CAS as defined below:\n\n  * Clinical definitions\n  * T2DM: Diagnosed according to the WHO criteria \\[53\\].\n  * CAD:Presence of any one of the following: Angina plus positive exercise tolerance test, enzyme and/or Q wave positive myocardial infarction, angiographic evidence ( \\>50% stenosis of one vessel), percutaneous or surgical coronary revascularisation.\n* Aged between 18 and 75\n* Provided written consent for participation in the trial prior to any study-specific procedures or requirements.\n* Must have minimum age of 18 Years\n* Must have maximum age of 75 Years",
    "exclusionCriteria": "* Contraindication to Clopidogrel\n* Smoking (current smokers and patients who quit smoking less than six months)\n* Malignancy(diagnosed or under investigation)\n* Haematological disorders (Anaemia, malignancy, bleeding disorders)\n* Women of child-bearing potential\n* Use of corticosteroids/other antithrombotic agents(warfarin)\n* Chronic liver disease (Cirrhosis, malignancy and patients with more than twice the upper limit of liver function tests)\n* Unable to consent.\n* Use of other investigational study drugs within 1 year prior to study entry\n* Previous participation in this study"
}